AAML 1421, a phase I/II study of CPX-351 followed by fludarabine, cytarabine, and G-CSF (FLAG) for children with relapsed acute myeloid leukemia (AML): A Report from the Children’s Oncology Group.
Year: 2019
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: University of Washington, Cincinnati Children's Hospital Medical Center, University of Southern California, Children's Oncology Group, Seattle Children's Hospital, University of Minnesota, Boston Children's Hospital, Dana-Farber Cancer Institute, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Peyton Manning Children’s Hospital at St.Vincent, Children's Hospital of Philadelphia, Children's Hospital at Montefiore
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2947795161